News Sentiment

CDNA sentiment intelligence

CareDx Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 28.51 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

85/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.3% over one week, +24.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

How Caredx Inc. (CDNA) Affects Rotational Strategy Timing

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 85/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 24.1% over four weeks
Fair value 68.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 31
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 6
simplywall.st 5
Business Wire 3
Investing.com Canada 3
Stock Traders Daily 2
TradingView 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 35
Deals and strategy 7
Regulatory and legal 3
Earnings 2
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Stock Traders Daily Direct company coverage

How Caredx Inc. (CDNA) Affects Rotational Strategy Timing

The article analyzes Caredx Inc. (CDNA) with a focus on its impact on rotational strategy timing, identifying weak near-term sentiment but compelling upside potential due to a lack of resistance levels above the current price. It presents three AI-generated trading strategies—Pos

Tone
Positive 67/100
Event
Market update
Published
13 Jul 2026 07:52
Source
Stock Traders Daily
TradingView Direct company coverage

Price to earnings forward of CareDx, Inc. – LSX:A118WG

This article provides the "Price to earnings forward" value for CareDx, Inc. (A118WG) on the Lang & Schwarz Exchange. The current value is not specified, but the piece indicates there is no current trading activity for the stock. It is a financial data point provided by TradingVi

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 00:39
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Caredx Inc For: 7 July By Investing.com

This article announces the filing of Form 4 for CareDx Inc. (CDNA) on July 7th. It reports a slight dip in the company's stock by 2.68% and invites comments on the filing.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 01:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

CareDx (CDNA) director receives 1,746-share quarterly stock grant as compensation

CareDx director Michael Goldberg received an automatic quarterly grant of 1,746 shares of Common Stock as compensation. This grant, valued at $0.00 per share, is part of the company's Outside Director Compensation Policy for non-employee directors. Following the transaction, Gold

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 01:12
Source
Stock Titan
Stock Titan Direct company coverage

CareDx (CDNA) exits lab products and acquires Naveris to expand $12B market

CareDx (CDNA) has streamlined its portfolio by selling its lab products business to Eurobio Scientific for $171.7 million and acquiring Naveris, Inc. for $161.8 million upfront plus potential milestones. This strategic move sharpens CareDx's focus on U.S. precision medicine testi

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2026 21:12
Source
Stock Titan
Market source Direct company coverage

CareDx Completes Naveris Acquisition and Expands Oncology Reach

CareDx has successfully acquired Naveris, integrating its NavDx test for HPV-positive cancers into CareDx's portfolio. This acquisition significantly expands CareDx's oncology reach and estimated U.S. addressable market to over $12 billion, strengthening its long-term growth pros

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 15:23
Source
Market source
TMX Newsfile Direct company coverage

CareDx Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against CareDx Inc. (NASDAQ: CDNA) and reminds investors of the July 22, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The investigation follows allegations that CareDx engaged in impr

Tone
Negative 9/100
Event
Regulatory and legal
Published
07 Jul 2026 01:12
Source
TMX Newsfile
Stock Titan Direct company coverage

CareDx (CDNA) CEO has 8,511 shares withheld for RSU tax obligations

CareDx, Inc.'s President and CEO, John Walter Hanna Jr., had 8,511 shares of common stock withheld by the company to cover tax obligations upon the vesting of restricted stock units. This transaction, valued at $29.25 per share, is a routine tax-withholding disposition and not an

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 19:40
Source
Stock Titan
Bloomberg Law News Direct company coverage

CareDx Leaders’ Audit Reforms Settlement Gets Court Approval

A US District Court judge has approved a settlement in which CareDx Inc. directors and executives agreed to implement audit reforms. This resolves a shareholder lawsuit alleging improper revenue-boosting schemes, including kickbacks and inaccurate marketing. The settlement also i

Tone
Negative 34/100
Event
Regulatory and legal
Published
06 Jul 2026 16:46
Source
Bloomberg Law News
TradingView Direct company coverage

Enterprise value to EBITDA forward of CareDx, Inc. – NASDAQ:CDNA

This article provides financial context for CareDx, Inc. (NASDAQ: CDNA) focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or data point from a financial platform, indicating the metric's value, change, and percentage change over a period. The cont

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 01:41
Source
TradingView
Finviz Direct company coverage

CDNA - Caredx Inc Short Interest

This article provides a detailed financial overview for Caredx Inc (CDNA), focusing on its short interest, key financial metrics, stock performance, and analyst recommendations. It highlights the company's market capitalization, income, sales, and various valuation ratios, alongs

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 11:39
Source
Finviz
Market source Direct company coverage

CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology

CareDx, Inc. announced its acquisition of Naveris, adding its blood-based viral-mediated cancer detection product, NavDx, to CareDx's portfolio. NavDx, which includes Medicare coverage for HPV-driven head and neck and anal cancer surveillance, is expected to significantly contrib

Tone
Positive 70/100
Event
Deals and strategy
Published
03 Jul 2026 07:42
Source
Market source
Stock Titan Direct company coverage

CareDx (CDNA) general counsel has 997 shares withheld for tax obligations

CareDx, Inc.'s Secretary and General Counsel, Jeffrey Adam Novack, had 997 shares of common stock withheld by the company to cover tax obligations related to the vesting of restricted stock units. This transaction, valued at $29.25 per share, is a routine administrative event and

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:11
Source
Stock Titan
Stock Titan Direct company coverage

CareDx (CDNA) CCO has shares withheld to cover taxes on RSU vesting

CareDx, Inc.'s Chief Commercial Officer, Jessica Meng, had 2,411 shares of common stock withheld by the company at $29.25 per share to cover tax obligations due to the vesting of restricted stock units. This transaction was a tax-related disposition, not an open-market sale. Foll

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

CareDx (CDNA) CFO & COO reports RSU tax withholding, holds 219,924 shares

CareDx Inc.'s CFO and COO, Keith Kennedy, reported a routine tax-related share disposition. The company withheld 2,930 shares of common stock at $29.25 per share to cover tax obligations from the vesting of restricted stock units. Following this, Kennedy directly holds 219,924 Ca

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:09
Source
Stock Titan
Clinical Lab Products Direct company coverage

Eurobio Scientific Finalizes Acquisition of CareDx Lab Product Division

Eurobio Scientific has completed its acquisition of CareDx's lab products division, including subsidiaries in the U.S., Sweden, and Australia, for approximately €145 million ($170 million). This strategic move integrates GenDx’s next-generation sequencing assays with CareDx’s tra

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Jul 2026 15:09
Source
Clinical Lab Products
Stock Traders Daily Direct company coverage

(CDNA) and the Role of Price-Sensitive Allocations

This article provides an AI-driven analysis of Caredx Inc. (NASDAQ: CDNA), highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It details three institutional trading strategies—Positio

Tone
Positive 75/100
Event
Market update
Published
02 Jul 2026 06:44
Source
Stock Traders Daily
MT Newswires Direct company coverage

CareDx Closes Naveris Acquisition

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 20:34
Source
MT Newswires
Business Wire Direct company coverage

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

CareDx (Nasdaq: CDNA) has successfully completed its acquisition of Naveris, a company specializing in diagnostics for viral-mediated cancers. The acquisition expands CareDx's addressable market to over $12 billion across transplant, specialty oncology, and cell therapy, integrat

Tone
Positive 72/100
Event
Deals and strategy
Published
01 Jul 2026 19:39
Source
Business Wire
www.marketscreener.com Direct company coverage

CareDx, Inc. completed the acquisition of Naveris, Inc. from B-Flexion Advisors (UK) LLP.

CareDx, Inc. has officially completed its acquisition of Naveris, Inc. from B-Flexion Advisors (UK) LLP. The deal, valued at an enterprise value of $160 million with potential for an additional $100 million based on revenue milestones, was initially agreed upon in April 2026. Gol

Tone
Positive 77/100
Event
Deals and strategy
Published
01 Jul 2026 11:12
Source
www.marketscreener.com
Moomoo Direct company coverage

CareDx Closes Sale of Lab Products Business to Eurobio Scientific

CareDx has successfully completed the sale of its Lab Products business to Eurobio Scientific. This strategic move allows CareDx to focus on its core transplant testing services and comprehensive patient care, while Eurobio Scientific will integrate the acquired product portfolio

Tone
Positive 60/100
Event
Market update
Published
01 Jul 2026 10:40
Source
Moomoo
GlobeNewswire Direct company coverage

Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division

Eurobio Scientific has completed its acquisition of CareDx’s Lab Products division, integrating it with its GenDx affiliate. This strategic move aims to create a global leader in in-vitro molecular diagnostics for transplantation, enhancing capabilities in genomic typing and expa

Tone
Positive 73/100
Event
Deals and strategy
Published
01 Jul 2026 05:39
Source
GlobeNewswire
Business Wire Direct company coverage

CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific

CareDx, Inc. has completed the sale of its Lab Products business to Eurobio Scientific for $171.2 million in cash, following regulatory clearance. This divestiture allows CareDx to sharpen its focus on U.S. Precision Medicine Testing Services and Patient and Digital Solutions, pa

Tone
Positive 67/100
Event
Regulatory and legal
Published
30 Jun 2026 22:39
Source
Business Wire
Stock Titan Direct company coverage

CareDx (CDNA) CEO exercises 70k options, sells 40k shares under 10b5-1 plan

CareDx (CDNA) President and CEO John Walter Hanna Jr. exercised employee stock options for 70,000 shares at $8.20 per share and subsequently sold 40,000 shares of common stock at a weighted average price of $29.244 per share. These sales, conducted on June 26 and June 29, 2026, w

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 22:39
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Caredx Inc For: 30 June By Investing.com

This article reports on a Form 4 filing for CareDx Inc. for June 30, as published by Investing.com. It indicates trading activity for the company (CDNA) with a slight stock performance decline. The main content also features various market data, including indices, commodities, an

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 21:40
Source
Investing.com Canada
Investing.com Canada Direct company coverage

CareDx president and CEO John Hanna sells $1.17m stock By Investing.com

CareDx's President and CEO, John Hanna, sold 40,000 shares of the company's common stock for approximately $1.17 million between June 26 and June 29, 2026, under a Rule 10b5-1 trading plan. Concurrently, Hanna acquired 60,000 shares through employee stock options for $574,000. Th

Tone
Negative 39/100
Event
Market update
Published
30 Jun 2026 21:34
Source
Investing.com Canada
Motley Fool Direct company coverage

CareDx's CEO Sells 17K Shares

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 01:58
Source
Motley Fool